Class I substance
|
No. of patients using the drug
|
References
|
---|
Amiodarone
|
12
|
[21], [22]
|
Atorvastatin
|
12
|
[11], [20]
|
Cyclosporine A
|
3
|
[23]
|
Dipyridamole
|
12
|
[24]
|
Quinidine
|
1
|
[1], [25]
|
Quinine
|
1
|
[26], [27]
|
Spironolactone
|
106
|
[25]
|
Verapamil
|
31
|
[25]
|
Class II substance
|
No. of patients using the drug
|
References
|
Bromocriptine
|
1
|
[28]
|
Flupentixol
|
1
|
[29]
|
Glibenclamide
|
46
|
[30]
|
Isradipine
|
2
|
[21], [31]
|
Lansoprazole
|
51
|
[32]
|
Loperamide
|
2
|
[33], [34]
|
Medroxyprogesterone
|
2
|
[35]
|
Omeprazole
|
35
|
[32]
|
Pantoprazole
|
6
|
[32]
|
Paroxetine
|
6
|
[36]
|
Sertraline
|
29
|
[36], [37]
|
Simvastatin
|
17
|
[20]
|
Terfenadine
|
1
|
[38]
|
- The coadministered drugs were classified for their effects on P-gp and on digoxin pharmacokinetics. Class I P-gp inhibitors have well-documented effects on digoxin pharmacokinetics in vivo, while Class II P-gp inhibitors have established P-gp inhibitory effects in vitro and putative effects on S-digoxin in vivo.